Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
Holding ERAS?
Track your performance easily
ERAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $3.45
Previous Close$2.78
Volume567.79K
Average Volume (3M)1.79M
Market Cap
$752.05M
Enterprise Value$520.01M
Total Cash (Recent Filing)$318.91M
Total Debt (Recent Filing)$52.94M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 20, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding282,727,282
10 Day Avg. Volume1,307,730
30 Day Avg. Volume1,792,477
Standard Deviation0.19
R-Squared0.10
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.75
Price to Sales (P/S)1450.39
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue901.23
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$5.00Price Target Upside87.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Erasca News
PremiumCompany Announcements
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
Bulls Say, Bears Say
Bulls Say
Innovative Treatment PotentialNaporafenib remains an innovative pan-RAF inhibitor, demonstrating promising potential as a first-in-class and best-in-class treatment option for NRASm melanoma, and potentially other RAS/MAPK pathway-driven tumors.
Promising Clinical OutcomesPooled analyses of NRASm melanoma patients treated with the combination at two doses showed promising median overall survival of 13.0 and 14.1 months, outperforming single-agent MEKi and standard chemotherapy.
Regulatory Support And Strategic FocusThe combination of naporafenib and trametinib has received Fast Track Designation for advanced NRASm melanoma and ERAS has received alignment on its approval strategy from both the US and EU regulatory agencies for a tissue-specific indication in melanoma.
Bears Say
Clinical Data SupportThe data did not support the company's 30-40% response rate threshold to pursue a tissue-agnostic approach.
Clinical StrategyDurable responses were only seen in melanoma patients, with no responses in CRC and PDAC patients, leading to a shift away from a tissue agnostic approach.
EfficacyEfficacy in non-melanoma tumor types was limited, with a 23% response rate, which was anticipated given the complex MAPK feedback across different tissue types.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.64 and its highest was $3.45 in the past 12 months.
What is Erasca’s market cap?
Currently, no data Available
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Mar 20, 2025 which is in 98 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Nov 12, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.057.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -$0.13.
How many shares outstanding does Erasca have?
Erasca has 282,727,300 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went down -4.682%.
Which hedge fund is a major shareholder of Erasca?
Among the largest hedge funds holding Erasca’s share is Woodline Partners LP. It holds Erasca’s shares valued at 11M.
---
Erasca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (87.97% Upside)
$5.00 (87.97% Upside)
Hedge Fund Trend
Increased
By 63.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.08%
12-Months-Change
Fundamentals
Return on Equity
-40.33%
Trailing 12-Months
Asset Growth
26.11%
Trailing 12-Months
Company Description
Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
---
ERAS Earnings Call
Q4 2024
0:00 / 0:00
---
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(87.97% Upside)
Technical Analysis
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+29.10%
reiterated a buy rating 30 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.10% per trade.
---